Overall, these findings indicate a positive impact of agalsidase alfa treatment on renal outcomes, as well as a stabilization or slowing of cardiomyopathy progression and delayed morbidity and mortality in treated patients when compared with untreated comparator cohorts. Here, GLA is linked to cardiomyopathy.